2012 U.S.D.A. ANNUAL REPORT

REGISTRATION NUMBER 22-R-0030, Customer # 178

COLUMN E EXPLANATIONS, EXEMPTIONS AND EXCEPTIONS

COLUMN E EXPLANATIONS

Two hundred and twelve hamsters developed acute terminal complications or were humanely euthanized in an IACUC-approved study to determine the protective effect of (b) (4) (b) (4) The use of pain relief and supportive care would alter the results of the study, therefore they were not used. The animals were closely monitored and those animals with significant health issues were humanely euthanized.

Five rabbits developed acute terminal complications on IACUC approved studies that evaluated (b) (4) administered to rabbits. The sudden nature did not allow medical intervention. Conduct of these procedures is required by the FDA and other foreign regulatory agencies (b) (4)

Six dogs in IACUC-approved studies developed medical complications of (b) (4) One remaining dog developed acute terminal complications. The studies examined whether there are (b) (4) The animals were closely monitored during the study by veterinary and research staff. The guidelines for (b) (4) (b) (4)

One dog on a (b) (4) study developed unexpected (b) (4) (b) (4) that were not responsive to symptomatic medical treatments. The study was approved by the IACUC.

Thirteen Non-Human Primates (eleven cynomolgus NHPs and two rhesus NHPs) developed medical complications while on an IACUC approved study (b) (4) in NHPs. The animals were closely monitored during the study by the veterinary and research staff. The cynomolgus NHPs developed (b) (4) and were euthanized in accordance to the humane end-point guidelines. The rhesus developed acute terminal complications. The (b) (4) are outlined in (b) (4) The studies were conducted in accordance with these guidelines and were approved by the IACUC.